Head and neck cancer researchers are reporting the development and testing of HPV-DeepSeek, a novel liquid biopsy assay. In their new study, HPV-DeepSeek achieved 99% sensitivty and specifity for diagnosing HPV-associated head and neck cancers, outperforming standard of care methods. HPV causes about 70% of oropharyngeal cancers in the U.S., which are increasing in incidence faster than other head and neck cancers.
